Anti-PDL-1-anti-TMIGD2 bispecific antibody - Astrazeneca
Alternative Names: CD28H-PDL1 bispecific antibodyLatest Information Update: 28 Jul 2024
At a glance
- Originator AstraZeneca
- Class Antineoplastics; Bispecific antibodies; Immunotherapies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Natural killer cell stimulants; Programmed cell death-1 ligand-1 inhibitors; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Jul 2024 No recent reports of development identified for preclinical development in Cancer in United Kingdom (Parenteral)
- 22 Jun 2020 Anti-PDL-1-anti-TMIGD2 bispecific antibody is available for licensing as of 22 Jun 2020. https://www.astrazeneca.com/partnering.html
- 22 Jun 2020 Preclinical development in Cancer in United Kingdom before June 2020 (Parenteral)